地西他滨对恶性脑膜瘤细胞的疗效:与特定抑癌和癌基因启动子去甲基化相关且不依赖TERT
该研究在两种良性(HBL-52和Ben-Men 1)和一种恶性(IOMM-Lee)脑膜瘤细胞系中,探讨去甲基化剂地西他滨对生存和DNA甲基化的影响。地西他滨(1至10 μM)剂量依赖性显著降低IOMM-Lee细胞的增殖和活力,但对良性细胞系无此效应,且该效应不依赖TERT表达、端粒酶活性或hTERT启动子甲基化。全基因组甲基化分析显示,在敏感的IOMM-Lee细胞中14个DNA区域发生明显去甲基化,覆盖11个基因的启动子区域,包括多个抑癌基因和癌基因。
要点
- 地西他滨降低高级别脑膜瘤细胞系IOMM-Lee的增殖和活力,但对良性脑膜瘤细胞系无显著影响。
- 地西他滨对IOMM-Lee细胞的作用不依赖TERT表达、端粒酶活性或hTERT启动子甲基化。
- 地西他滨诱导敏感细胞中14个DNA区域去甲基化,涉及11个基因启动子,包括抑癌基因和癌基因。
核心结论
- 地西他滨降低高级别而非良性脑膜瘤细胞系的增殖和活力。
- 地西他滨的作用不依赖TERT,但与特定抑癌基因和癌基因启动子的DNA甲基化改变相关。
研究设计与样本
- 在两种良性(HBL-52和Ben-Men 1)和一种恶性(IOMM-Lee)脑膜瘤细胞系中,于地西他滨孵育前后检测hTERT启动子甲基化、端粒酶活性、TERT表达、细胞活力和增殖。
- 另用DNA甲基化谱分析探讨地西他滨对DNA甲基化的全局影响。
主要发现
- IOMM-Lee和Ben-Men 1细胞中TERT表达、端粒酶活性和hTERT启动子甲基化水平高,而HBL-52细胞中不高。
- 地西他滨在1至10 μM剂量下剂量依赖性显著降低IOMM-Lee细胞的增殖和活力,但对HBL-52或Ben-Men 1细胞无此效应。
- IOMM-Lee细胞中的效应与TERT表达、端粒酶活性或hTERT启动子甲基化无关。
- 全基因组甲基化分析显示,给药后地西他滨敏感的IOMM-Lee细胞中14个DNA区域发生明显去甲基化,而耐药HBL-52细胞中无此变化。
- 差异甲基化区域覆盖11个基因的启动子区域,包括多个抑癌基因和癌基因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chemotherapeutic options for meningiomas refractory to surgery or irradiation are largely unknown. Human telomerase reverse transcriptase (hTERT) promoter methylation with subsequent TERT expression and telomerase activity, key features in oncogenesis, are found in most high-grade meningiomas. Therefore, the authors investigated the impact of the demethylating agent decitabine (5-aza-2'-deoxycytidine) on survival and DNA methylation in meningioma cells. METHODS: hTERT promoter methylation, telomerase activity, TERT expression, and cell viability and proliferation were investigated prior to and after incubation with decitabine in two benign (HBL-52 and Ben-Men 1) and one malignant (IOMM-Lee) meningioma cell line. The global effects of decitabine on DNA methylation were additionally explored with DNA methylation profiling. RESULTS: High levels of TERT expression, telomerase activity, and hTERT promoter methylation were found in IOMM-Lee and Ben-Men 1 but not in HBL-52 cells. Decitabine induced a dose-dependent significant decrease of proliferation and viability after incubation with doses from 1 to 10 μM in IOMM-Lee but not in HBL-52 or Ben-Men 1 cells. However, effects in IOMM-Lee cells were not related to TERT expression, telomerase activity, or hTERT promoter methylation. Genome-wide methylation analyses revealed distinct demethylation of 14 DNA regions after drug administration in the decitabine-sensitive IOMM-Lee but not in the decitabine-resistant HBL-52 cells. Differentially methylated regions covered promoter regions of 11 genes, including several oncogenes and tumor suppressor genes that to the authors' knowledge have not yet been described in meningiomas. CONCLUSIONS: Decitabine decreases proliferation and viability in high-grade but not in benign meningioma cell lines. The effects of decitabine are TERT independent but related to DNA methylation changes of promoters of distinct tumor suppressor genes and oncogenes.
引用
- Stögbauer L, Thomas C, Wagner A, et al. Efficacy of decitabine in malignant meningioma cells: relation to promoter demethylation of distinct tumor suppressor and oncogenes and independence from TERT. J Neurosurg. 2020. PMID: 33307532. doi:10.3171/2020.7.JNS193097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。